{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:13:21Z","timestamp":1793193201291,"version":"4.5.0"},"reference-count":40,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,2,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To determine the efficacy and safety of supplemental therapeutic oxygen for infants with prethreshold retinopathy of prematurity (ROP) to reduce the probability of progression to threshold ROP and the need for peripheral retinal ablation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Premature infants with confirmed prethreshold ROP in at least 1 eye and median pulse oximetry &amp;lt;94% saturation were randomized to a conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation or a supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints. Certified examiners masked to treatment assignment conducted weekly eye examinations until each study eye reached ophthalmic endpoint. An adverse ophthalmic endpoint for an infant was defined as reaching threshold criteria for laser or cryotherapy in at least 1 study eye. A favorable ophthalmic endpoint was regression of the ROP into zone III for at least 2 consecutive weekly examinations or full retinal vascularization. At 3 months after the due date of the infant, ophthalmic findings, pulmonary status, growth, and interim illnesses were again recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Six hundred forty-nine infants (325 conventional and 324 supplemental) were enrolled from 30 centers over 5 years. Five hundred ninety-seven (92.0%) infants attained known ophthalmic endpoints, and 600 (92%) completed the ophthalmic 3-month assessment. The rate of progression to threshold in at least 1 eye was 48% in the conventional arm and 41% in the supplemental arm. After adjustment for baseline ROP severity stratum, plus disease, race, and gestational age, the odds ratio (supplemental vs conventional) for progression was .72 (95% confidence interval: .52, 1.01). Final structural status of all study eyes at 3 months of corrected age showed similar rates of severe sequelae in both treatment arms: retinal detachments or folds (4.4% conventional vs 4.1% supplemental), and macular ectopia (3.9% conventional vs 3.9% supplemental). Within the prespecified ROP severity strata, ROP progression rates were lower with supplemental oxygen than with conventional oxygen, but the differences were not statistically significant. A post hoc subgroup analysis of plus disease (dilated and tortuous vessels in at least 2 quadrants of the posterior pole) suggested that infants without plus disease may be more responsive to supplemental therapy (46% progression in the conventional arm vs 32% in the supplemental arm) than infants with plus disease (52% progression in conventional vs 57% in supplemental).<\/jats:p><jats:p>Pneumonia and\/or exacerbations of chronic lung disease occurred in more infants in the supplemental arm (8.5% conventional vs 13.2% supplemental). Also, at 50 weeks of postmenstrual age, fewer conventional than supplemental infants remained hospitalized (6.8% vs 12.7%), on oxygen (37.0% vs 46.8%), and on diuretics (24.4% vs 35.8%). Growth and developmental milestones did not differ between the 2 arms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Use of supplemental oxygen at pulse oximetry saturations of 96% to 99% did not cause additional progression of prethreshold ROP but also did not significantly reduce the number of infants requiring peripheral ablative surgery. A subgroup analysis suggested a benefit of supplemental oxygen among infants who have prethreshold ROP without plus disease, but this finding requires additional study. Supplemental oxygen increased the risk of adverse pulmonary events including pneumonia and\/or exacerbations of chronic lung disease and the need for oxygen, diuretics, and hospitalization at 3 months of corrected age. Although the relative risk\/benefit of supplemental oxygen for each infant must be individually considered, clinicians need no longer be concerned that supplemental oxygen, as used in this study, will exacerbate active prethreshold ROP.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.105.2.295","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:50:41Z","timestamp":1092441041000},"page":"295-310","source":"Crossref","is-referenced-by-count":627,"title":["Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A Randomized, Controlled Trial. I: Primary Outcomes"],"prefix":"10.1542","volume":"105","author":[{"name":"The STOP-ROP Multicenter Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2000,2,1]]},"reference":[{"key":"2021121003033198600_B1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group.","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"key":"2021121003033198600_B2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.1994.01090190051021","article-title":"The natural ocular outcome of premature birth and retinopathy: status at 1 year.","volume":"112","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: three-month outcome.","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: one-year outcome\u2014structure and function.","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0161-6420(91)32247-4","article-title":"Laser photocoagulation for stage 3+ retinopathy of prematurity.","volume":"98","author":"McNamara","year":"1991","journal-title":"Ophthalmology"},{"key":"2021121003033198600_B6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archopht.1994.01090140028007","article-title":"Laser therapy for retinopathy of prematurity.","volume":"112","author":"Clarkson","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archopht.1996.01100130413008","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 5 1\/2 years after randomization.","volume":"114","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B8","first-page":"137","article-title":"The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases.","volume":"68","author":"Michaelson","year":"1948","journal-title":"Trans Ophthalmol Soc UK"},{"key":"2021121003033198600_B9","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/0002-9394(53)90792-2","article-title":"Retrolental fibroplasia and related ocular diseases: classification, etiology, and prophylaxis.","volume":"36","author":"Szewczyk","year":"1953","journal-title":"Am J Ophthalmol"},{"key":"2021121003033198600_B10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archopht.1955.00930010520008","article-title":"Effect of oxygen weaning in retrolental fibroplasia.","volume":"53","author":"Bedrossian","year":"1955","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9394(54)92034-6","article-title":"Retinopathy of prematurity (retrolental fibroplasia) and oxygen: part I. Clinical study: part II. Further observations on the disease.","volume":"37","author":"Bedrossian","year":"1954","journal-title":"Am J Ophthalmol"},{"key":"2021121003033198600_B12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archopht.1956.00930040489001","article-title":"Retrolental fibroplasia: cooperative study of retrolental fibroplasia and the use of oxygen.","volume":"56","author":"Kinsey","year":"1956","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.60.5.655","article-title":"Pao2 levels and retrolental fibroplasia: a report of the cooperative study.","volume":"60","author":"Kinsey","year":"1977","journal-title":"Pediatrics"},{"key":"2021121003033198600_B14","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1542\/peds.65.6.1096","article-title":"Risk factors in retrolental fibroplasia.","volume":"65","author":"Gunn","year":"1980","journal-title":"Pediatrics"},{"key":"2021121003033198600_B15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.80.6.972","article-title":"Hypoxemia and retinopathy of prematurity.","volume":"80","author":"Katzman","year":"1987","journal-title":"Pediatrics"},{"key":"2021121003033198600_B16"},{"key":"2021121003033198600_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.73.1.1","article-title":"Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model.","volume":"73","author":"Phelps","year":"1984","journal-title":"Pediatrics"},{"key":"2021121003033198600_B18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1203\/00006450-198807000-00024","article-title":"Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen.","volume":"24","author":"Phelps","year":"1988","journal-title":"Pediatr Res"},{"key":"2021121003033198600_B19"},{"key":"2021121003033198600_B20"},{"key":"2021121003033198600_B21"},{"key":"2021121003033198600_B22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0197-2456(88)90048-7","article-title":"Properties of the urn randomization in clinical trials.","volume":"9","author":"Wei","year":"1988","journal-title":"Control Clin Trials"},{"key":"2021121003033198600_B23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJM199805283382202","article-title":"Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT- ROP) Cooperative Group.","volume":"338","author":"Reynolds","year":"1998","journal-title":"N Engl J Med"},{"key":"2021121003033198600_B24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1542\/peds.74.1.127","article-title":"An international classification of retinopathy of prematurity.","volume":"74","author":"International Committee for Classification of ROP","year":"1984","journal-title":"Pediatrics"},{"key":"2021121003033198600_B25"},{"key":"2021121003033198600_B26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0022-3476(87)80573-5","article-title":"Revision of Denver Prescreening Developmental Questionnaire.","volume":"110","author":"Frankenburg","year":"1987","journal-title":"J Pediatr"},{"key":"2021121003033198600_B27"},{"key":"2021121003033198600_B28","first-page":"434","article-title":"Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity.","volume":"17","author":"Gaynon","year":"1997","journal-title":"J Perinatol"},{"key":"2021121003033198600_B29","first-page":"S820","article-title":"Oxygen therapy in acute retinopathy of prematurity stage 3.","volume":"39","author":"Seiberth","year":"1988","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021121003033198600_B30","first-page":"1215","article-title":"Supplemental oxygen therapy: basis for noninvasive treatment of retinopathy of prematurity.","volume":"36","author":"Chan-Ling","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021121003033198600_B31","first-page":"1201","article-title":"The effect of oxygen on vasoformative cell division: evidence that \u201cphysiological hypoxia\u201d is the stimulus for normal retinal vasculogenesis.","volume":"36","author":"Chan-Ling","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021121003033198600_B32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1091-8531(97)90008-2","article-title":"Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity.","volume":"1","author":"Young","year":"1997","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"2021121003033198600_B33","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"2021121003033198600_B34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","article-title":"Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity.","volume":"114","author":"Pierce","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"2021121003033198600_B35","first-page":"2063","article-title":"The range of Pao2 variation determines the severity of oxygen-induced retinopathy in newborn rats.","volume":"36","author":"Penn","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021121003033198600_B36"},{"key":"2021121003033198600_B37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archpedi.1994.02170030064015","article-title":"Maximizing the stability of oxygen delivered via nasal cannula.","volume":"148","author":"Benaron","year":"1994","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2021121003033198600_B38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2307\/2530924","article-title":"Exact confidence intervals following a group sequential test.","volume":"40","author":"Tsiatis","year":"1984","journal-title":"Biometrics"},{"key":"2021121003033198600_B39","first-page":"992","article-title":"Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia.","volume":"141","author":"Groothuis","year":"1987","journal-title":"Am J Dis Child"},{"key":"2021121003033198600_B40","first-page":"357","article-title":"Home oxygen therapy for chronic lung disease in extremely low-birth-weight infants.","volume":"143","author":"Hudak","year":"1989","journal-title":"Am J Dis Child"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/105\/2\/295\/887921\/pe020000295p.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/105\/2\/295\/887921\/pe020000295p.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:35:01Z","timestamp":1682746501000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/105\/2\/295\/62563\/Supplemental-Therapeutic-Oxygen-for-Prethreshold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2000,2,1]]},"published-print":{"date-parts":[[2000,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.105.2.295","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2,1]]}}}